IRT in Infants With Intestinal Perforation
Immunoreactive Trypsinogen in Infants With Intestinal Perforation
1 other identifier
observational
300
1 country
1
Brief Summary
This study is designed to evaluate a novel tool to aid in the diagnosis of intestinal perforation in infants who are at high risk. Analysis of perforation rates of all infants in the three largest participating sites shows that the majority of infants with perforation will do so prior to day of life 21. This study will target the group of infants at highest risk for IP, those with birth weight less than 1000 grams, within the time frame most likely to capture the perforation. Hypothesis: An IRT value exists that can adequately differentiate premature infants with and without intestinal perforation in the first 3 weeks of life.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2010
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2010
CompletedFirst Submitted
Initial submission to the registry
February 8, 2012
CompletedFirst Posted
Study publicly available on registry
February 10, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2014
CompletedAugust 9, 2013
August 1, 2013
3.1 years
February 8, 2012
August 7, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To determine the onset and duration of elevation in serum IRT in infants with intestinal perforation.
3 years
Secondary Outcomes (1)
Determine if factors other than intestinal perforation affect serum IRT.
3 years
Study Arms (1)
Premature infants
Weight less than 1000 grams, age 1 - 16 days.
Eligibility Criteria
Premature infants less than 1000 grams, age 1-16 days
You may qualify if:
- Informed consent
- Birth weight less than 1000 grams
- Admitted to investigative site within first 16 days of life.
You may not qualify if:
- Evidence of Intestinal perforation in utero
- Suspected or confirmed custic fibrosis
- Abdominal wall defect or intestinal atresia
- Concomitant medical condition that may create an unacceptable risk.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Children's Hospitals & Clinics of Minnesota
Saint Paul, Minnesota, 55102, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prinicpal Investigator
Study Record Dates
First Submitted
February 8, 2012
First Posted
February 10, 2012
Study Start
August 1, 2010
Primary Completion
September 1, 2013
Study Completion
August 1, 2014
Last Updated
August 9, 2013
Record last verified: 2013-08